Spelling suggestions: "subject:"[een] LUPUS"" "subject:"[enn] LUPUS""
11 |
Comparison of mycophenolate mofetil and cyclophosphamide on inflammatory and fibrotic processes in the pathogenesis of lupus nephritis : animal and in vitro studies /Zhang, Qing, January 2009 (has links)
Thesis (Ph. D.)--University of Hong Kong, 2009. / Includes bibliographical references (leaves 238-276). Also available online.
|
12 |
Comparison of mycophenolate mofetil and cyclophosphamide on inflammatory and fibrotic processes in the pathogenesis of lupus nephritis animal and in vitro studies /Zhang, Qing, January 2009 (has links)
Thesis (Ph. D.)--University of Hong Kong, 2009. / Includes bibliographical references (leaves 238-276). Also available in print.
|
13 |
Systemic lupus erythematosus in Hong Kong /Wong, Kee-lam. January 1900 (has links)
Thesis (M.D.)--University of Hong Kong, 1991.
|
14 |
Systemic lupus erythematosus in Hong KongWong, Kee-lam. January 1900 (has links)
Thesis (M.D.)--University of Hong Kong, 1991. / Also available in print.
|
15 |
Cost of systemic lupus erythematosus in Hong Kong /Fan, Hiu-yi, Rosie. January 2005 (has links)
Thesis (M. Res.)--University of Hong Kong, 2005.
|
16 |
DNA and the DNA immune complex in systemic lupus erythematosus.Klemp, Patrick 20 April 2017 (has links)
No description available.
|
17 |
Hsp 90 in lupus-prone miceFaulds, Gary Bryan January 1995 (has links)
No description available.
|
18 |
Production and analysis of human monoclonal IgG anti-DNA antibodiesEhrenstein, Michael Randolph January 1995 (has links)
No description available.
|
19 |
The identification of novel susceptibility genes in the lupus prone BXSB mouseMaibaum, Michael Anthony January 2001 (has links)
No description available.
|
20 |
The effect of immunosuppressants in a mouse model of glomerulonephritisGill, Diana J. January 1994 (has links)
This study compared the effect of various immunosuppressive therapies on the development of lupus nephritis using a murine model of SLE, the MRL lpr/lpr mouse. The agents investigated were cyclosporin A (CsA), FK506, rapamycin and mycophenolate mofetil (MM). Female MRL lpr/lpr mice at 12 weeks old were treated with CsA (40mg/kg/day p.o.), FK506 (2.5mg/kg/3 times/week or/day s.c.), rapamycin (1.5mg/kg.day s.c.), MM (50mg/kg/2 times daily p.o.) or vehicle controls. These groups were compared with untreated MRL lpr/lpr and also untreated MRL +/+ mice which do not develop this autoimmune disease. Disease progression was assessed using various markers for SLE and glomerular dysfunction. The results obtained showed CsA and rapamycin to both inhibit glomerular proliferation and reduce glomerular macrophage infiltrate. In addition, rapamycin also reduced chronic inflammatory cell infiltrate, lymphadenopathy and splenomegaly. Rapamycin treated animals did not develop skin lesions and alopecia which became apparent on mice from other groups. In contrast neither low or high dose FK506 treatments prevented the development of the autoimmune pathological features, including renal disease. Likewise, mycophenolate mofetil had no beneficial effects in disease prevention. In conclusion, it appears that both rapamycin and CsA but not FK506 or mycophenolate mofetil reduce macrophage infiltration, glomerular proliferation and, in the case of rapamycin chronic inflammatory cell infiltrate and lymphadenopathy, in the MRL lpr/lpr mouse.
|
Page generated in 0.0251 seconds